Author:
Torcasso Madeleine S.,Howard Frederick M.,Zha Yuanyuan,Ai Junting,Clark Marcus R.,Giger Maryellen L.
Reference21 articles.
1. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
2. E. Hahnen et al., “Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial,” (in eng), no. 2374–2445 (Electronic).
3. S. Loibl et al., “Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial,” (in eng), no. 1474–5488 (Electronic).
4. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
5. Pembrolizumab for Early Triple-Negative Breast Cancer